Literature DB >> 33599033

Human brain pathology in myotonic dystrophy type 1: A systematic review.

Ralf Weijs1,2, Kees Okkersen2, Baziel van Engelen2, Benno Küsters3, Martin Lammens4, Eleonora Aronica5, Joost Raaphorst5, Anne-Marie van Cappellen van Walsum1.   

Abstract

Brain involvement in myotonic dystrophy type 1 (DM1) is characterized by heterogeneous cognitive, behavioral, and affective symptoms and imaging alterations indicative of widespread grey and white matter involvement. The aim of the present study was to systematically review the literature on brain pathology in DM1. We conducted a structured search in EMBASE (index period 1974-2017) and MEDLINE (index period 1887-2017) on December 11, 2017, using free text and index search terms related to myotonic dystrophy type 1 and brain structures or regions. Eligible studies were full-text studies reporting on microscopic brain pathology of DM1 patients without potentially interfering comorbidity. We discussed the findings based on the anatomical region and the nature of the anomaly. Neuropathological findings in DM1 can be classified as follows: (1) protein and nucleotide deposits; (2) changes in neurons and glial cells; and (3) white matter alterations. Most findings are unspecific to DM1 and may occur with physiological aging, albeit to a lesser degree. There are similarities and contrasts with Alzheimer's disease; both show the appearance of neurofibrillary tangles in the limbic system without plaque occurrence. Likewise, there is myelin loss and gliosis, and there are dilated perivascular spaces in the white matter resemblant of cerebral small vessel disease. However, we did not find evidence of lacunar infarction or microbleeding. The various neuropathological findings in DM1 are reflective of the heterogeneous clinical and neuroimaging features of the disease. The strength of conclusions from this study's findings is bounded by limited numbers of participants in studies, methodological constraints, and lack of assessed associations between histopathology and clinical or neuroimaging findings.
© 2021 The Authors. Neuropathology published by John Wiley & Sons Australia, Ltd on behalf of Japanese Society of Neuropathology.

Entities:  

Keywords:  brain; microscopic pathology; myotonic dystrophy; systematic review

Year:  2021        PMID: 33599033     DOI: 10.1111/neup.12721

Source DB:  PubMed          Journal:  Neuropathology        ISSN: 0919-6544            Impact factor:   1.906


  5 in total

1.  Cell type-specific abnormalities of central nervous system in myotonic dystrophy type 1.

Authors:  Masayuki Nakamori; Hiroshi Shimizu; Kotaro Ogawa; Yuhei Hasuike; Takashi Nakajima; Hidetoshi Sakurai; Toshiyuki Araki; Yukinori Okada; Akiyoshi Kakita; Hideki Mochizuki
Journal:  Brain Commun       Date:  2022-06-10

Review 2.  Cellular Senescence and Aging in Myotonic Dystrophy.

Authors:  Yuhei Hasuike; Hideki Mochizuki; Masayuki Nakamori
Journal:  Int J Mol Sci       Date:  2022-02-20       Impact factor: 5.923

3.  Blood-Based Markers of Neuronal Injury in Adult-Onset Myotonic Dystrophy Type 1.

Authors:  Ellen van der Plas; Jeffrey D Long; Timothy R Koscik; Vincent Magnotta; Darren G Monckton; Sarah A Cumming; Amy C Gottschalk; Marco Hefti; Laurie Gutmann; Peggy C Nopoulos
Journal:  Front Neurol       Date:  2022-01-20       Impact factor: 4.003

4.  Elevated serum Neurofilament Light chain (NfL) as a potential biomarker of neurological involvement in Myotonic Dystrophy type 1 (DM1).

Authors:  Tommaso F Nicoletti; Salvatore Rossi; Maria Gabriella Vita; Alessia Perna; Gisella Guerrera; Federica Lino; Chiara Iacovelli; Daniele Di Natale; Anna Modoni; Luca Battistini; Gabriella Silvestri
Journal:  J Neurol       Date:  2022-05-16       Impact factor: 6.682

5.  DM1 Transgenic Mice Exhibit Abnormal Neurotransmitter Homeostasis and Synaptic Plasticity in Association with RNA Foci and Mis-Splicing in the Hippocampus.

Authors:  Brigitte Potier; Louison Lallemant; Sandrine Parrot; Aline Huguet-Lachon; Geneviève Gourdon; Patrick Dutar; Mário Gomes-Pereira
Journal:  Int J Mol Sci       Date:  2022-01-06       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.